Compare · CCXI vs INV
CCXI vs INV
Side-by-side comparison of Churchill Capital Corp XI (CCXI) and Innventure Inc. (INV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCXI and INV operate in Blank Checks (Finance), so they compete in similar markets.
- INV carries a market cap of $14.7M.
- Over the past year, CCXI is up 8.8% and INV is down 95.9% - CCXI leads by 104.7 points.
- CCXI has been more active in the news (49 items in the past 4 weeks vs 14 for INV).
- CCXI has more recent analyst coverage (8 ratings vs 2 for INV).
Churchill Capital Corp XI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Latest CCXI
- Chief Operating Officer Hunter Jennifer was granted 3,220,699 stock options (SEC Form 4)
- Officer Lang Anastasia was granted 2,760,599 stock options (SEC Form 4)
- Director Shelton Damion was granted 9,938,151 shares (SEC Form 4)
- Chief Technology Officer Velagapudi Prasanna was granted 3,680,797 stock options (SEC Form 4)
- Chief Financial Officer Beer Michael Thomas was granted 2,576,560 shares (SEC Form 4)
- Chief Executive Officer Johnson Margaret L was granted 347,790 shares (SEC Form 4)
- Chief Robot Officer Hurst Jonathan was granted 12,422,709 shares (SEC Form 4)
- Chief Hardware Officer Marroquin Marco was granted 2,300,498 stock options (SEC Form 4)
- President Diez Daniel was granted 3,220,699 stock options (SEC Form 4)
- SEC Form 3 filed by new insider Hunter Jennifer
Latest INV
- SEC Form 10-Q filed by Innventure Inc.
- Innventure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Innventure Reports Third Quarter 2026 Results
- Innventure to Announce Third Quarter 2026 Results on November 12, 2026
- Accelsius Provides Two-Phase Direct-to-Chip Cooling to Support NSF ES2 Energy Efficiency Research at Villanova University
- Innventure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Innventure Announces Formation of Strategic Review Committee to Review Range of Capital Strategies
- SEC Form 3 filed by Innventure Inc.
- SEC Form 8-K filed by Innventure Inc.
- INV UPCOMING DEADLINE: Levi & Korsinsky Alerts Innventure, Inc. Stockholders of Securities Class Action - Contact the Firm